Discontinued — last reported Q1 '18
Hubbell Allowance for Doubtful Accounts Receivable (Current) increased by 2.9% to $14.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 18.2%, from $12.10M to $14.30M. Over 5 years (FY 2020 to FY 2025), Allowance for Doubtful Accounts Receivable (Current) shows an upward trend with a 2.1% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
A significant increase relative to receivables may signal deteriorating customer credit quality or economic headwinds in specific markets.
This is a contra-asset account representing the estimated amount of accounts receivable that the company expects will no...
Standard across all industries; peers in the medical device sector typically maintain low levels unless operating in high-risk emerging markets.
allowance_for_doubtful_accounts_receivable_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $11.80M | $11.60M | $10.60M | $11.50M | $13.90M | $14.80M | $14.30M | $13.90M | $13.60M | $13.20M | $11.60M | $11.40M | $10.90M | $11.40M | $11.30M | $12.10M | $13.30M | $13.40M | $13.90M | $14.30M |
| QoQ Change | — | -1.7% | -8.6% | +8.5% | +20.9% | +6.5% | -3.4% | -2.8% | -2.2% | -2.9% | -12.1% | -1.7% | -4.4% | +4.6% | -0.9% | +7.1% | +9.9% | +0.8% | +3.7% | +2.9% |
| YoY Change | — | — | — | — | +17.8% | +27.6% | +34.9% | +20.9% | -2.2% | -10.8% | -18.9% | -18.0% | -19.9% | -13.6% | -2.6% | +6.1% | +22.0% | +17.5% | +23.0% | +18.2% |